ID: MRFR/HC/7027-HCR | February 2021 | Region: Global | 90 pages
Seborrheic Dermatitis Treatment Market is expected to cross USD 3.28 Billion by 2025 at a CAGR of 10.5 %.
Seborrheic dermatitis is a chronic inflammatory disorder that mostly affects the head and face. Primarily environmental, genetic, and general health problems are the cause of this disorder. The exact cause of seborrheic dermatitis remains unknown, but factors such as a change in hormone is the primary cause of this disease. It frequently affects people post-puberty. The prevalence of seborrheic dermatitis has been rising significantly in recent years. In the US alone, approximately 300 people are diagnosed with seborrheic dermatitis annually making it a reasonably common dermatological disorder worldwide. Some factors influencing the market growth are the rising awareness of personal hygiene, advancement in treatment options for seborrheic dermatitis, and growing awareness regarding seborrheic dermatitis.
Development in the seborrheic dermatitis treatment is expected to influence the market growth during the forecast period.
By Treatment Type
By Route of Administration
Frequently Asked Questions (FAQ) :
seborrheic dermatitis market is projected grow at approximately 10.5% CAGR during the assessment period (2019-2025).
The valuation of the global seborrheic dermatitis market is estimated to increase to USD 3.28 BN by the end of 2025.
The corticosteroid lotions segment by treatment type holds the majority shares in the global seborrheic dermatitis market.
North America holds the largest share in the global seborrheic dermatitis market, followed by Europe and the Asia Pacific, respectively.
Merck (US), Sonoma Pharmaceuticals (US), Hikma Pharmaceuticals (UK), GlaxoSmithKline (UK), Allen and Hanburys (UK), Bausch Health (Canada), West-Ward Pharmaceutical Corp. (US), and Valent Pharmaceutical (UK), are some of the major players operating in the global seborrheic dermatitis market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.